Ateleva
Ateleva is developing a minimally invasive airway platform that enables selective reinflation and localized treatment of collapsed lung segments in critically ill and surgical patients. Unlike non-selective methods like ventilator recruitment or bronchoscopy, the device provides controlled, segment-level reinflation without increasing pressure across the entire lung. The technology is investigational with patents pending and is designed to integrate seamlessly with existing bronchoscopy workflows.
- Medical Devices
- Healthcare Technology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Current management strategies for collapsed lung segments are non-selective and not designed for segment-level therapy. Clinicians rely on ventilator recruitment, bronchoscopy, airway clearance, and supportive techniques such as proning and physiotherapy, which either increase pressure across the entire lung or provide indirect clearance without restoring ventilation to the specific collapsed region. During interventional procedures, bronchoscopy enables visualization and suction but cannot achieve controlled reinflation of an isolated segment, leaving collapsed segments untreated and procedural access compromised.
Solution
Ateleva is developing a minimally invasive airway platform that enables selective reinflation and localized treatment of collapsed lung segments in critically ill and surgical patients. The device provides temporary segmental airway isolation and controlled, localized reinflation, targeting specific areas without increasing pressure across the entire lung. It is designed to integrate seamlessly with existing bronchoscopy workflows, requiring no new capital equipment or complex training. The technology is currently investigational, with patents pending and pending regulatory review.
Target Audience
Primary users are clinicians managing critically ill and surgical patients with collapsed lung segments, including intensivists, pulmonologists, and interventional bronchoscopists in hospital and procedural settings.
Features
- Temporary segmental airway isolation for targeted access to collapsed lung regions
- Controlled, localized reinflation that restores ventilation to specific segments without whole-lung pressure increases
- Seamless integration with existing bronchoscopy workflows, eliminating the need for new capital equipment
- No complex training required for clinicians to adopt the device
- Patents pending on the underlying airway platform technology